Next Article in Journal
The Singularity of the Drosophila Male Germ Cell Centriole: The Asymmetric Distribution of Sas4 and Sas6
Next Article in Special Issue
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Previous Article in Journal
MicroRNAs: Biological Regulators in Pathogen–Host Interactions
Previous Article in Special Issue
Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs’ World
Open AccessReview

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

1
Institute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany
2
Comprehensive Cancer Center (CCC) Erlangen-EMN, 91054 Erlangen, Germany
3
Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(1), 114; https://doi.org/10.3390/cells9010114
Received: 27 November 2019 / Revised: 20 December 2019 / Accepted: 23 December 2019 / Published: 2 January 2020
(This article belongs to the Special Issue microRNA as Therapeutic Target)
In this review, we summarize the current knowledge on miRNAs as therapeutic targets in two cancer types that were frequently described to be driven by miRNAs—melanoma and hepatocellular carcinoma (HCC). By focusing on common microRNAs and associated pathways in these—at first sight—dissimilar cancer types, we aim at revealing similar molecular mechanisms that are evolved in microRNA-biology to drive cancer progression. Thereby, we also want to outlay potential novel therapeutic strategies. After providing a brief introduction to general miRNA biology and basic information about HCC and melanoma, this review depicts prominent examples of potent oncomiRs and tumor-suppressor miRNAs, which have been proven to drive diverse cancer types including melanoma and HCC. To develop and apply miRNA-based therapeutics for cancer treatment in the future, it is essential to understand how miRNA dysregulation evolves during malignant transformation. Therefore, we highlight important aspects such as genetic alterations, miRNA editing and transcriptional regulation based on concrete examples. Furthermore, we expand our illustration by focusing on miRNA-associated proteins as well as other regulators of miRNAs which could also provide therapeutic targets. Finally, design and delivery strategies of miRNA-associated therapeutic agents as well as potential drawbacks are discussed to address the question of how miRNAs might contribute to cancer therapy in the future. View Full-Text
Keywords: miRNA; melanoma; hepatocellular carcinoma; liver cancer; let-7; miR-622; mir-26a; miR-221; miR-210 miRNA; melanoma; hepatocellular carcinoma; liver cancer; let-7; miR-622; mir-26a; miR-221; miR-210
Show Figures

Figure 1

MDPI and ACS Style

Linck-Paulus, L.; Hellerbrand, C.; Bosserhoff, A.K.; Dietrich, P. Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. Cells 2020, 9, 114. https://doi.org/10.3390/cells9010114

AMA Style

Linck-Paulus L, Hellerbrand C, Bosserhoff AK, Dietrich P. Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. Cells. 2020; 9(1):114. https://doi.org/10.3390/cells9010114

Chicago/Turabian Style

Linck-Paulus, Lisa; Hellerbrand, Claus; Bosserhoff, Anja K.; Dietrich, Peter. 2020. "Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma" Cells 9, no. 1: 114. https://doi.org/10.3390/cells9010114

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop